Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
Da-Liang OuChia-Wei ChenChia-Lang HsuChih-Hung ChungZi-Rui FengBin-Shyun LeeAnn-Lii ChengMuh-Hwa YangChiun HsuPublished in: Journal for immunotherapy of cancer (2021)
Regorafenib may enhance antitumor immunity through modulation of macrophage polarization, independent of its anti-angiogenic effects. Optimization of regorafenib dosage for rational design of combination therapy regimen may improve the therapeutic index in the clinic.